How Can Companies Manage AI Patent Inventorship Risk in 2025?

USPTO Inventorship Guidance for AI

Companies navigating AI patent strategy in 2025 face a shifting landscape following the USPTO's revised inventorship guidance for AI-assisted inventions. The guidance confirms that a natural person must make a significant contribution to each claimed invention, but it also clarifies that using AI tools does not disqualify an inventor if that person meaningfully shaped the invention's conception. For companies in AI drug discovery and other R&D-intensive fields, this means documenting how human researchers prompt, evaluate, and refine AI outputs is now essential to establishing valid inventorship. Failing to name the correct inventors can render patents invalid or unenforceable, so internal protocols for recording human contributions should be established before filing.

Also worth reading: How Can a Responsible AI Patent Strategy Balance Innovation, Inventorship, and Trade Secrets? · AI Patent Inventorship Review: Who Receives Credit for AI Contributions? · AI Patent Inventorship Records: Who Must Be Named on AI-Assisted Patents in 2026?

Beyond patent filings, companies should weigh trade secret protection for AI-generated innovations where human contribution is thin or difficult to document. Recent developments, including the Supreme Court's refusal to hear the AI authorship case, suggest courts will not soon extend inventorship to machines. A dual-track strategy—patents where human inventors clearly contribute, trade secrets where they do not—offers the most defensible path forward.

Supreme Court Denies AI Inventorship Case

The Supreme Court's refusal to hear the Thaler v. Vidal line of cases leaves the legal landscape settled for now: under current U.S. law, only natural persons can be named as inventors, and purely AI-generated inventions cannot be patented. For companies deploying AI in research and development, particularly in drug discovery and other AI-intensive fields, the practical question is no longer whether AI can be an inventor but how to structure workflows so that human contribution is genuine, documented, and defensible. The USPTO's revised inventorship guidance from earlier this year emphasizes that AI-assisted inventions remain patentable when a significant human contribution can be identified, making internal recordkeeping and inventor identification processes more important than ever.

Companies should audit their innovation pipelines now. That means training scientists and engineers on what constitutes a significant contribution, capturing contemporaneous evidence of human design choices and experimentation, and deciding deliberately between patent protection and trade secret strategies for AI-generated outputs. Firms that treat inventorship analysis as a routine gate in their disclosure process, rather than an afterthought at filing, will be far better positioned when examiners, courts, or competitors scrutinize their patents.

Trade Secrets Versus AI Patents

Companies deploying AI in their innovation pipelines face a persistent question in 2025: who is the inventor? The USPTO's revised inventorship guidance for AI-assisted inventions confirms that only natural persons can be named inventors, but it also clarifies that humans who make a significant contribution to AI-assisted output can qualify. This creates real risk for companies that rely heavily on machine-generated discoveries, particularly in fields like AI drug discovery, where the line between human conception and machine output is increasingly blurred. Misnaming inventors, or omitting a true inventor, can render a patent invalid or unenforceable.

Practical management of this risk requires deliberate documentation. Companies should record how engineers, scientists, or researchers prompt, select, refine, and validate AI outputs, building an evidentiary trail of significant human contribution. Where human contribution is genuinely minimal, trade secret protection may be the better strategy, since it imposes no inventorship requirement. A portfolio review that sorts candidate innovations between patent and trade secret pathways, informed by counsel's assessment of inventorship strength, is now an essential governance step.

Diligence Risks in AI Acquisitions

Companies can manage AI patent inventorship risk in 2025 by treating the USPTO’s revised guidance as a diligence checklist, not a formality. Because inventorship turns on whether a natural person made a significant contribution to each claim, acquirers should demand claim-by-claim documentation of human conception and reduce AI’s role to assistance. Inventions conceived solely by AI remain unpatentable, so targets must show that named inventors actually conceived the claimed subject matter.

In practice, this means auditing invention disclosures, lab notebooks, prompt histories, and model outputs before signing. Sellers should obtain assignments from every contributing person and correct inventorship errors early, since mistakes can invalidate patents. Given the Supreme Court’s refusal to hear the AI authorship case, uncertainty persists, so buyers should pair patent filings with trade secret protections for AI-generated know-how.

Drafting Patents with Generative AI

Companies navigating AI patent inventorship risk in 2025 face a landscape shaped by the USPTO's revised guidance for AI-assisted inventions, which reaffirms that only natural persons can be named as inventors while clarifying when human contribution rises to the level of patentable conception. Firms using generative AI in drug discovery and other R&D-intensive fields should document how prompts, training data, and human selections shape claimed inventions, since the guidance emphasizes significant human contribution to each claimed element. Failure to maintain contemporaneous records could jeopardize patent validity or trigger ownership disputes.

Beyond patent doctrine, trade secret protection offers an alternative for AI-generated innovations that may not satisfy inventorship requirements, and recent developments—including the Supreme Court's refusal to hear the AI authorship case—suggest courts will defer to existing human-centric frameworks for now. Companies should also monitor inventor networks during acquisitions, as analysis of deal activity like Danaher's interest in Masimo highlights how talent and inventorship records affect valuation. A coordinated patent-and-trade-secret strategy, paired with rigorous AI use documentation, remains the most effective risk management approach.

Patents vs. Trade Secrets for AI Inventions

Companies in 2025 should conduct inventor network analyses and audit AI contributions before filing. The USPTO’s revised guidance demands clear human conception, while the Supreme Court’s refusal to hear AI authorship cases leaves uncertainty. A hybrid approach—patenting core human-designed elements and protecting AI training pipelines as trade secrets—mitigates inventorship risk and preserves competitive advantage.